These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 32229549)
41. Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection--authors' reply. Fischer M; Rex DK; Sipe BW Aliment Pharmacol Ther; 2015 Oct; 42(8):1031. PubMed ID: 26374259 [No Abstract] [Full Text] [Related]
42. Oral fidaxomicin versus vancomycin for Clostridioides difficile infection. Long B; Gottlieb M Acad Emerg Med; 2022 Dec; 29(12):1506-1507. PubMed ID: 36156832 [No Abstract] [Full Text] [Related]
43. The 'ins and outs' of faecal microbiota transplant for recurrent Clostridium difficile diarrhoea at Wits Donald Gordon Medical Centre, Johannesburg, South Africa. Lee S; Drennan K; Simons G; Hepple A; Karlsson K; Lowman W; Gaylard PC; McNamara L; Fabian J S Afr Med J; 2018 Apr; 108(5):403-407. PubMed ID: 29843854 [TBL] [Abstract][Full Text] [Related]
44. Fidaxomicin and Fecal Microbiota Transplants for Severe Clostridium difficile Colitis. Mankal PK; Abed J; Latte-Naor S; Grinspan A; Kotler DP Am J Ther; 2019; 26(1):e115-e117. PubMed ID: 30601771 [No Abstract] [Full Text] [Related]
45. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Tannock GW; Munro K; Taylor C; Lawley B; Young W; Byrne B; Emery J; Louie T Microbiology (Reading); 2010 Nov; 156(Pt 11):3354-3359. PubMed ID: 20724385 [TBL] [Abstract][Full Text] [Related]
46. Update of treatment algorithms for Clostridium difficile infection. Ooijevaar RE; van Beurden YH; Terveer EM; Goorhuis A; Bauer MP; Keller JJ; Mulder CJJ; Kuijper EJ Clin Microbiol Infect; 2018 May; 24(5):452-462. PubMed ID: 29309934 [TBL] [Abstract][Full Text] [Related]
47. Fidaxomicin in the treatment of Clostridium difficile infection in oncohematology patients. Martín Rizo L; Malpartida Flores M; Fernández Lisón LC Med Clin (Barc); 2019 Oct; 153(7):298-299. PubMed ID: 30337114 [No Abstract] [Full Text] [Related]
48. Diagnosis and Treatment of Clostridium difficile Infection. Gupta A; Cifu AS; Khanna S JAMA; 2018 Sep; 320(10):1031-1032. PubMed ID: 30178042 [No Abstract] [Full Text] [Related]
49. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. Polivkova S; Krutova M; Capek V; Sykorova B; Benes J Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906 [TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease. You JHS; Jiang X; Lee WH; Chan PKS; Ng SC J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248 [TBL] [Abstract][Full Text] [Related]
52. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile. Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052 [TBL] [Abstract][Full Text] [Related]
53. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. Gentry CA; Nguyen PK; Thind S; Kurdgelashvili G; Skrepnek GH; Williams RJ Clin Microbiol Infect; 2019 Aug; 25(8):987-993. PubMed ID: 30583055 [TBL] [Abstract][Full Text] [Related]
54. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856 [TBL] [Abstract][Full Text] [Related]
55. Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection. Rafiullah F; Kanwal S; Majeed UM; Korsten MA; Cheema FH; Luthra M; Sohail MR BMJ Case Rep; 2011 Nov; 2011():. PubMed ID: 22674696 [TBL] [Abstract][Full Text] [Related]
56. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability? Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970 [TBL] [Abstract][Full Text] [Related]
57. Fecal transplantation - the new, inexpensive, safe, and rapidly effective approach in the treatment of gastrointestinal tract diseases. Oprita R; Bratu M; Oprita B; Diaconescu B J Med Life; 2016; 9(2):160-2. PubMed ID: 27453747 [TBL] [Abstract][Full Text] [Related]
58. Challenges and opportunities in the management of Clostridium difficile infection. DuPont HL Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):863-74. PubMed ID: 25012255 [TBL] [Abstract][Full Text] [Related]
59. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials. Madoff SE; Urquiaga M; Alonso CD; Kelly CP Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500 [TBL] [Abstract][Full Text] [Related]
60. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ; Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]